The Endotine bioabsorbable implant is commonly used to help with providing structural support for soft tissue elevation during specific aesthetic surgical procedures.

Addressing Symptoms Related to Facial Tissue Descent

The device is applied in aesthetic surgical settings to address the effects of age-related soft tissue descent. This includes specifically managing conditions like brow ptosis (drooping eyebrows), the sagging of the midface region, and the resultant aesthetic symptoms such as deep forehead creases and the flattening of cheek contours. The device is relevant when visible tissue laxity may assist with resolving an expression that appears tired or concerned.

This type of fixation is commonly used to help with securing surgically repositioned facial tissues during the critical healing period.

Supporting Structural Stability During Healing Phases

The device provides supportive relief by offering secure, multi-point internal fixation to maintain the elevated position of surgically repositioned soft tissues. This structural support is considered appropriate during the critical post-operative healing phase to support the tissue remaining anchored until the body establishes its own long-term biological attachment. The resultant benefit supports an aesthetic outcome that can contribute to maintaining the surgical correction, which contributes to improved comfort by easing the overall symptom load of visible aging.

---

Quick Fact: Relief for Tissue Laxity The implant plays a role in managing symptoms of significant tissue laxity and descent by providing temporary, stable fixation, which is commonly used during episodes of surgical facial rejuvenation.

Regulatory References

1. FDA 510(k) Premarket Notification Summary

Who Can and Cannot Use ENDOTINE Fixation Devices?

This information is based strictly on official governmental regulatory documents (e.g., FDA, Health Canada, EMA) and defines the eligibility profile for ENDOTINE bioabsorbable devices, which are used for internal fixation.

---

Eligibility Constraints

Restricted Use: ENDOTINE devices are classified as Prescription Use only. This means the device may be sold, distributed, or used only by or on the order of a physician. The general public is ineligible to use or purchase this device.

Contraindicated Populations: The use of ENDOTINE is formally contraindicated (prohibited) for specific patient groups to ensure safety and fixation success. These include:

• Patients with known allergies or foreign-body sensitivities to plastic biomaterial.
• Patients who are in a situation where internal fixation is otherwise contraindicated (such as the presence of an infection at the operative site).
• Patients who appear to have very thin soft tissues in the area where the device is intended for placement (e.g., the midface when using the corresponding device).

Regulatory documents do not explicitly list specific age, pregnancy, or lactation status restrictions, but they mandate physician oversight to determine final patient eligibility based on the contraindications and overall clinical status.

Interactions with other medicines and products

Official regulatory documentation on interactions for Endotine is defined by its classification as a Class II medical device, which is a non-pharmacological, bioabsorbable surgical implant. As a structural device made of synthetic polymers (Polylactic Acid and Polyglycolic Acid), Endotine contains no active drug substance. This means the implant does not engage in the systemic pharmacological interactions typically documented for active pharmaceutical ingredients.

---

Interaction Scope and Official Profile

Category	Official Regulatory Status
Documented Pharmacological Interactions	None
Interacting Medicines	None listed
Metabolic or Transporter Basis	Not applicable

---

Interaction-Related Restrictions

Official regulatory documents from government health authorities, such as the FDA, do not list specific drug-drug, drug-food, or drug-substance interactions for Endotine. Because the device's action is solely mechanical—providing temporary soft tissue fixation—it does not alter the exposure of co-administered medicines, nor do medicines alter the systemic profile of the device's components.

There are no mandatory timing separation rules for the co-administration of oral or injectable medicines due to interaction risk with the implant. The absence of entries in the standard pharmacological interaction domains confirms that no restrictions related to metabolic, pharmacokinetic, or pharmacodynamic interactions are required by regulatory bodies.

The function of Endotine, a bioabsorbable surgical implant, relies on a sequenced mechanism of biomechanical fixation followed by biological tissue integration.

---

Initial Mechanical Stabilization and Tension Distribution

The mechanism begins with Temporary Mechanical Stabilization, engaging the soft tissue envelope and cranial bone via multipoint fixation. This immediate action uses the device’s specialized tines to distribute mechanical forces, opposing the intrinsic tissue tension following repositioning. This physical stabilization provides continuous mechanical resistance necessary for maintaining the repositioned tissue vector during the initial healing period.

---

Biological Integration and Long-Term Scaffold Formation

Following mechanical placement, the implant supports the Fibrous Tissue Integration Pathway. The device acts as a temporary internal scaffolding, influencing the local environment to facilitate the deposition of collagen and fibrous tissue around the anchor points. This biological process establishes a new, integrated fibrous scaffold, which gradually assumes the load-bearing function as the implant's mechanical properties diminish.

---

Material Hydrolysis and Systemic Clearance

The final mechanistic domain involves the Material Hydrolysis Pathway, where the PLA/PGA polymer is broken down into water-soluble molecules. This process of full absorption results in the complete elimination of the polymer, coincident with the formation of the integrated fibrous scaffold during the healing phase.

How to Use Endotine: Official Administration Guidelines

Endotine is a brand of bioabsorbable soft tissue fixation devices used in surgical procedures, not a pharmaceutical drug. Its use is governed by established surgical protocols and device specifications.

---

Administration Scope and Dosing

Category	Official Requirement
Route of Administration	Surgical Implantation to underlying bone (e.g., cranial bone or facial bone) via surgical incision. Placement is typically subperiosteal.
Dosing Schedule	Single-Use Only. The device is manufactured for one-time use and must never be re-used.
Preparation	Supplied pre-sterilized. Do not use if the package is compromised and do not resterilize.

---

Procedural and Component Specifications

Proper use requires adherence to specific surgical steps and component usage:

• Bone Preparation: A hole must be prepared in the bone using the specific drill bit with a stop collar provided in the system to ensure adequate depth and avoid injury.
• Insertion: The device is inserted using the dedicated Insertion Tool and pushed straight down until the implant platform is flush with the cranium or bone surface.
• Tissue Engagement: Digital pressure must be applied to the soft tissue (scalp, etc.) to ensure the tines properly penetrate and engage the tissue to achieve secure, multipoint fixation.
• Age/Constraint: The device is contraindicated in patients with inadequate cranial or facial bone thickness at the intended fixation site.

The device provides temporary fixation for the soft tissue during the critical initial healing period until biological attachment is complete. It is gradually absorbed by the body over time.

Research Evidence: Overview of Studies for Endotine

This section reviews the structure of the scientific studies conducted on the Endotine device. It focuses only on what the research examined, what findings were observed, and where uncertainty remains, without offering any clinical advice or making claims about personal outcomes.

Evidence for Soft Tissue Fixation in Browplasty (Forehead Lift)

Research exploring the use of Endotine for soft tissue fixation during brow and forehead lifting was evaluated in systematic reviews, non-comparative case series, and small observational studies. Researchers generally monitored the short-term and intermediate-term outcomes by using objective tools to track changes in brow position. Studies also examined patient-reported experiences related to their satisfaction.

Findings describe patterns observed in the studies related to the measured changes in brow position observed during the initial follow-up period (typically a few months to two years). However, findings were mixed across various reports regarding the stability of the position over longer periods, and there appears to be substantial variability between individual study results.

Evidence for Subperiosteal Midface Suspension

Research on this application was evaluated in retrospective chart reviews and case series. Studies monitored the changes in midfacial height using validated measurement scales and assessed the aesthetic results through surgeon and patient-reported outcomes describing perceived discomfort.

Evidence is limited for this indication compared to the brow fixation research. Sample sizes were modest in many of the published reports, and comparative evidence is lacking to fully understand how this approach contrasts with other midface lifting or tissue suspension techniques.

Long-Term Studies and Follow-Up Data

Research has explored the longevity of the surgical observation by following patient groups for extended periods. These studies were evaluated in order to understand the maintenance of tissue position after the bioabsorbable device has dissolved. Long-term effects are not fully established by evidence with the highest level of certainty. Follow-up durations were limited in many of the initial reports.

What is Still Uncertain About the Research for Endotine

A review of the available research indicates several areas where knowledge appears to be incomplete. Comparative evidence is lacking from large, controlled studies that directly compare the use of the Endotine device against all other contemporary fixation techniques. While various studies exist, the evidence quality varies across studies, leading to some inconsistency in reported findings.

Common questions about Endotine (FAQ)

Q: Is Endotine intended for cosmetic procedures, functional procedures, or both?

According to the official product information, the device is indicated for soft tissue fixation, which allows its use in the context of both aesthetic (cosmetic) and reconstructive surgery. The ultimate determination of whether a procedure addresses a cosmetic or functional concern is decided by the treating physician.

Q: How long does the Endotine implant take to dissolve and be absorbed by the body?

Endotine is designed to be fully bioabsorbable. Regulatory documents state that the implant material is typically absorbed by the body over a period of several months. For example, the classic Forehead device is often absorbed in approximately 9 to 12 months, though this timeframe can vary by the specific model used.

Q: Can Endotine be used for a brow lift that is medically necessary due to vision issues (functional ptosis)?

Official documentation indicates the device’s use in subperiosteal browplasty surgery for fixing soft tissue to the cranial bone. The decision to use the device for a functional purpose, such as correcting vision issues, is made by the physician based on a patient's diagnosis and medical needs.

Q: Are there any long-term side effects associated with the device material?

The material (PLA/PGA) is fully absorbed by the body. Documented risks that may occur prior to full absorption include potential for prolonged absorption time or discomfort over the implant. Safety profiles for the polymer material have noted that the typical local host response is commonly described as usually mild inflammation.

Q: Are there different surgical approaches (endoscopic vs. open) where Endotine can be used?

Yes. The Instructions for Use (IFU) specify that the device is intended for use in both endoscopic (minimally invasive) and open techniques for soft tissue fixation, allowing for flexibility in the surgical approach.

Q: Can the Endotine implant cause any discomfort when sleeping or applying pressure to the area?

Official adverse event information indicates that patients may experience tenderness and visible fullness (palpability) over the device for several months after the procedure. This temporary discomfort may be more noticeable when external pressure, such as sleeping on the area, is applied.

Q: How is Endotine different from traditional sutures or screws used in lift procedures?

Endotine is characterized by its patented MultiPoint Technology (MPT™) and multiple-tine design. This design feature is intended to distribute mechanical forces across the soft tissue via multiple points of contact, which is the device's unique mechanism for achieving fixation.

Q: Are there different versions or sizes of the Endotine device?

Yes. The Instructions for Use (IFU) document that the device is available in various models and sizes, such as 3.0mm and 3.5mm tines, and different platform designs (like Forehead and TransBleph). These specific designs are optimized for use in different anatomical areas and tissue thicknesses.

Q: If the Endotine implant can be felt, how long does that palpability usually last?

Palpability, or the ability to feel the device under the skin, is a documented adverse event. The official Instructions for Use note that this visible fullness or tenderness over the device may be present for several months before the device is fully absorbed by the body.

Q: Is there a risk of hair loss around the area where Endotine is placed?

Risk information associated with the device indicates that thinning of the hair or skin over the implant is a possible complication in some cases.

Q: What is the timeframe for seeing the final results after a procedure using Endotine?

The device is designed to provide temporary fixation during the critical initial healing period until biological tissue attachment is complete. The full aesthetic outcome is generally achieved after this initial healing and stabilization process is complete.

Q: Can a patient request to have the Endotine implant removed before it dissolves naturally?

Yes, although the device is bioabsorbable, explantation (surgical removal) is possible. The official product information indicates that if a patient experiences significant sensitivity or discomfort, the implant may be removed by the surgeon, which requires an additional procedure.

Q: Is Endotine used in conjunction with other facial cosmetic procedures?

Official procedural documents confirm that certain models are designed for use through incisions made for other procedures. For example, the TransBleph device is intended for use via an upper eyelid incision often made for a conventional blepharoplasty (eyelid surgery).

Q: Does the use of Endotine in a brow lift produce a 'pulled' or unnatural appearance?

According to the Instructions for Use, the device is described as adjustable, allowing the surgeon to maintain optimal control of the brow height and shape during the procedure. This adjustability is intended to help the surgeon achieve the desired aesthetic result.

Q: What kind of anesthesia is typically used for a procedure involving Endotine?

Official procedural notes indicate that, depending on the specific device model and the scope of the surgery, the procedure can be performed under local anesthesia with intravenous sedation or general anesthesia.

Q: Why is Endotine referred to as 'bioabsorbable' instead of 'dissolvable'?

The term 'bioabsorbable' is used because the polymer breaks down via Material Hydrolysis, an active biological process within the body. This process transforms the material into water-soluble molecules that are then systematically cleared by the body.

Q: Do surgeons need special training or certification to use the Endotine device?

The device is classified as Prescription Use and may only be used by or on the order of a physician. The manufacturer advises surgeons to rely on their professional clinical judgment and refer to specific procedural documents provided with the device.

Q: Can the Endotine implant be adjusted after the surgery is complete?

The Instructions for Use state that the device is adjustable. This feature is designed to allow the surgeon to precisely readjust the position of the secured tissue during the initial placement phase of the procedure.

Q: Does Endotine affect the movement or expression of the facial muscles?

Official safety information lists Nerve Injury or Irritation as a potential adverse event. This is the documented mechanism by which both sensation and/or motor function (muscle movement) in the surgical area could be temporarily or permanently affected.

Q: Does the material of the Endotine device cause any inflammatory response in the body?

Yes. Official safety profiles for the polymer material (PLA/PGA) note that the most common local host response reported in studies is inflammation, which is usually described as mild. This response is considered part of the material's breakdown as part of the healing process.

How to Store and Dispose of Endotine? — Official Regulatory Requirements

Endotine is a sterile, single-use, resorbable soft tissue fixation device. Its official storage and disposal requirements are established in the product's labeling, as approved by governmental regulatory bodies (such as the FDA).

Official Storage and Handling

Requirement	Classification
Temperature	Store at room temperature
Protection	Protect from excessive heat, direct sunlight, and moisture (keep dry)
Package Integrity	Keep in the original, sealed package; do not use if opened or damaged
Use Status	Device is for single use only; do not re-sterilize

Disposal Instructions

After use, the device and all accessories must be disposed of as contaminated medical waste or biohazardous waste. Disposal must strictly adhere to the facility's policies and all applicable local, state, and federal regulatory guidelines for medical waste.